StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.51−0.02 (-3.73%)

Close on Nov 16, 2026Market cap $78.16MP/E –Yield –

Coherus Oncology total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

No total debt figures for Coherus Oncology

Coherus Oncology has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Coherus Oncology figures

See a number that looks wrong?